CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, February 19, 2026

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) has announced a rescheduled investor conference call set for Thursday, February 19, 2026, at 3 PM Central Time. This announcement replaces the previous release dated February 17, 2026, to correct multiple revisions. The call will delve into the company's innovative approaches concerning cardiovascular disease prevention and detection, highlighting advancements in its existing tests, Epi+Gen CHD™ and PrecisionCHD™. The session will also cover new clinical data, reimbursement developments, and strategic initiatives aimed at fostering growth.

Investors can join the call via a webcast at the following link: [Cardio Diagnostics Webcast](https://www.cstproxy.com/cardiodiagnosticsinc/investorday/2026). For those wishing to participate by phone, U.S. and Canada participants can use the toll-free number 1-800-450-7155, while international callers should dial +1 857-999-9155. A passcode of 3253181# will be required for access. Following the presentation, a replay will be made available at the webcast link.

Cardio Diagnostics specializes in precision cardiovascular medicine, utilizing artificial intelligence, genetics, and epigenetics to enhance accessibility and precision in cardiovascular disease management. The company was established to advance the development and commercialization of clinical tests focused on cardiovascular health. Interested parties can learn more about Cardio Diagnostics and its mission through their official website at [cdio.ai](https://cdio.ai/).

The release includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, which are subject to various risks and uncertainties that could influence the company's results. Investors are encouraged to consider these factors when interpreting the company's future performance. For more detailed insights, individuals can also reach out to Cardio Diagnostics' Investor Relations at 855-226-9991 or via email at investors@cdio.ai.

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) is set to host an informative investor call on February 19, 2026, offering a closer look at its precision molecular approach to cardiovascular disease (CVD). As a financial analyst, the restructured narrative surrounding this call may attract both current investors and potential stakeholders concerned about the evolving landscape of cardiovascular diagnostics.

The company is leveraging cutting-edge technologies, including epigenetics and artificial intelligence, which could differentiate it from traditional diagnostics companies. The call will specifically highlight key offerings like Epi+Gen CHD™ and PrecisionCHD™, emphasizing their potential to transform CVD prevention and detection. Investors should keenly watch for updates on clinical data and reimbursement progress—two critical indicators that could influence the adoption and financial viability of these tests.

Moreover, the strategic growth initiatives discussed may offer insight into the company's long-term vision and ability to capitalize on market opportunities, especially as healthcare increasingly shifts towards personalized medicine.

For investors, the timing of this call is particularly relevant, with the broader market context reflecting heightened interest in digital health solutions and precision medicine. As Cardio Diagnostics continues to address pervasive cardiovascular issues—exacerbated by an aging population—its growth potential appears robust.

However, it is crucial to remain cautious. The forward-looking statements included in the press release point to the inherent risks of executing growth strategies amid evolving regulations and economic conditions. Investors should prepare for variations in performance as these risks materialize.

In conclusion, the upcoming investor call represents a pivotal moment for Cardio Diagnostics, reinforcing its commitment to innovation in the cardiovascular space. Analysts and investors alike should monitor the outputs from this call closely, as it may set the stage for significant developments in the company's trajectory.